Th17细胞在肝脏疾病中的免疫病理作用

doi:10.3969/j.issn.1672-5069.2010.03.031

摘要/Abstract

摘要： Th17细胞是效应性CD4⁺T细胞家族的新成员,由IL-6、TGF-β和IL-23等细胞因子诱导和维持分化,通过分泌IL-17、IL-21和IL-22等细胞因子参与炎症、自身免疫性疾病、肿瘤、移植排斥等过程。近年研究证实Th17细胞与多种肝脏疾病有关。

晁康, 龚晓蓉, 陈湖, 钟碧慧. Th17细胞在肝脏疾病中的免疫病理作用[J]. 实用肝脏病杂志, 2010, 13(3): 224-226.

[1] HARRINGTON LE,HATTON RD,MANGAN PR,et al. Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol,2005,6（11）:1123-1132.
[2] PARK H,LI Z,YANG XO,et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol,2005,6（11）:1133-1141.
[3] KITA H,MACKAY IR,VAN DE WATER J,et al. The lymphoid liver：considerations on pathways to autoimmune injury[J]. Gastroenterology,2001,120（6）：1485-1501.
[4] MOSMANN TR,COFFMAN RL. Th1 and Th2 cells:different patterns of lymphokine secretion lead to different functional properties[J]. Annu Rev Immunol,1989,7:145-173.
[5] BASSO AS,CHEROUTRE H,MUCIDA D. More stories on Th17 cells[J]. Cell Res,2009,19（4）:399-411.
[6] KOMIYAMA Y,NAKAE S,MATSUKI T,et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis[J]. J Immunol,2006,177（1）：566-573.
[7] HOFSTETTER HH,IBRAHIM SM,KOCZAN D,et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis[J]. Cell Immunol,2005,237（2）：123-130.
[8] NAKAE S,NAMBU A,SUDO K,et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice[J]. J Immunol,2003,171（11）：6173-6177.
[9] ZENEWICZ LA,ANTOV A,FLAVELL RA. CD4 T-cell differentiation and inflammatory bowel disease[J]. Trends Mol Med,2009,15（5）：199-207.
[10] HUANG Z,XIE H,WANG R,et al. Retinoid-related orphan receptor gamma is a potential therapeutic target for controlling inflammatory autoimmunity[J]. Expert Opin Ther Targets,2007,11（6）：737-743.
[11] CECILE KING,STUART G,TANG YE,et al. T follicular helper（TFH）cells in normal and dysregulated immune responses[J]. Annu Rev Immunol,2008,26：741-66.
[12] KORN T,BETTELLI E,OUKKA M,et al. IL-17 and Th17 cells[J]. Annu Rev Immunol,2009,27：485-517.
[13] LAN RY,SALUNGA TL,TSUNEYAMA K,et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis[J]. J Autoimmun,2009,32（1）：43-51.
[14] RONG G,ZHOU Y,XIONG Y,et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis：the serum cytokine profile and peripheral cell population[J]. Clin Exp Immunol,2009,156（2）：217-225.
[15] HARADA K,SHIMODA S,SATO Y,et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis[J]. Clin Exp Immunol,2009,157（2）：261-270.
[16] MILICH DR. Influence of T-helper cell subsets and cross regulation in hepatitis B virus infection[J]. J Viral Hepat,1997,4 Suppl 2：48-59.
[17] MANIGOLD T,RACANELLI V. T-cell regulation by CD4 regulatory T cell during hepatitis B and C virus infections：facts and controversies[J]. Lancet Infect Dis,2007,7（12）：804-813.
[18] GE J,WANG K,MENG QH,et al. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B[J]. J Clin Immunol,2009,30（1）：60-67.
[19] 秦来英,杜文军,刘葵花,等. 白细胞介素17的肝内表达与慢性乙型肝炎肝纤维化的相关性[J]. 中华肝脏病杂志,2009,17（3）：221-222.
[20] ZHANG JY,ZHANG Z,LIN F,et al. Interleukin-17-producing CD4（+）T cells increase with severity of liver damage in patients with chronic hepatitis B[J].Hepatology,2010,51（1）：81-91.
[21] DAMBACHER J,BEIGEL F,ZITZMANN K,et al. The role of interleukin-22 in hepatitis C virus infection[J].Cytokine,2008,41（3）：209-216.
[22] LEMMERS A,MORENO C,GUSTOT T,et al. The interleukin-17 pathway is involved in human alcoholic liver disease[J]. Hepatology,2009,49（2）：646-657.
[23] CALDWELL CC,OKAYA T,MARTIGNONI A,et al. Divergent functions of CD4+T lymphocytes in acute liver inflammation and injury after ischemia-reperfusion[J]. Am J Physiol Gastrointest Liver Physiol, 2005,289（5）：G969-976.
[24] YASUMI Y,TAKIKAWA Y,ENDO R,et al. Interleukin-17 as a new marker of severity of acute hepatic injury[J]. Hepatol Res,2007,37（4）：248-254.
[25] RADAEVA S,SUN R,PAN HN,et al. Interleukin 22（IL-22）plays a protective role in T cell-mediated murine hepatitis：IL-22 is a survival factor for hepatocytes via STAT3 activation[J]. Hepatology,2004,39（5）：1332-1342.
[26] ZENEWICZ LA,YANCOPOULOS GD,VALENZUELA DM,et al. IL-22 but not IL-17 provides protection to hepatocytes during acute liver inflammation[J]. Immunity,2007,27（4）：647-659.
[27] MANTOVANI A,ALLAVENA P,SICA A,et al. Cancer-related inflammation[J]. Nature,2008,454（7203）：436-444.
[28] ZHANG JP,YAN J,XU J,et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients[J]. J Hepatol,2009,50（5）：980-989.
[29] FÁBREGA E,LÓPEZ-HOYOS M,SAN SEGUNDO D, et al. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation[J]. Liver Transpl,2009,15（6）：629-633.
[30] FÁBREGAE,LÓPEZ-HOYOS M,SAN SEGUNDO D, et al. Effect of immuno- suppressant blood levels on serum concentration of interleukin-17 and -23 in stable liver transplant recipients[J]. Transplant Proc,2009,41（3）：1025-1027.

Th17细胞在肝脏疾病中的免疫病理作用

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[2]	杨东亮, 刘嘉, 吴珺, 郑昕. 肝脏免疫学研究若干进展与挑战[J]. 实用肝脏病杂志, 2019, 22(5): 609-612.
[3]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[4]	蔡美洪, 王绮夏, 马雄. 肝内胆管缺失的病理生理学研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 620-623.
[5]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.
[6]	张骏飞, 许何明, 宋海燕, 董静, 潘劲劲, 陈照林, 徐军, 陈从新, 刘波. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征：巴黎标准诊断中国患者灵敏度低[J]. 实用肝脏病杂志, 2019, 22(4): 537-540.
[7]	叶一农. HBsAg血清清除后的维持治疗[J]. 实用肝脏病杂志, 2019, 22(3): 318-320.
[8]	周炎仪, 阳灿. 雷公藤多甙片联合异甘草酸镁治疗自身免疫性肝炎患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(3): 365-368.
[9]	周积云,马勇,丁体龙,涂远航,陈策. 慢性乙型肝炎患者外周血CD8⁺CD28⁺T淋巴细胞百分比的变化及其临床意义探讨[J]. 实用肝脏病杂志, 2019, 22(2): 180-183.
[10]	彭小燕,徐莉娟,刘鹏,祁双宝,孙一鸣. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动程度的关系及对治疗应答的影响^*[J]. 实用肝脏病杂志, 2019, 22(2): 200-203.
[11]	林兰,沈敏,阮健文. 自身免疫性肝炎患者肝组织程序性死亡受体1表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 204-207.
[12]	陈永其, 陈前, 袁春艳, 刘军, 谢蕴. 肝细胞癌癌组织和癌旁肝组织Ep-CAM和C-Kit表达及其意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 109-112.
[13]	代晓楠, 吕金燕, 翁文采, 郑丽丽. 肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 117-120.
[14]	徐国荣, 柴丽莉. 乙肝疫苗联合乙型肝炎免疫球蛋白接种阻断血清HBsAg阳性母亲HBV母婴传播效果分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 851-854.
[15]	夏庚综述, 祁飞, 杨晋辉审校. 自身免疫性肝炎诱发因素研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 983-986.